Nizwaside: a new anticancer pregnane glycoside from the sap of Desmidorchis flava

• Published in: Archives of pharmacal research 2015, 38(12), , pp.2137-2142
• Main Authors: Hussain, Hidayat, Raees, Muhammad Adil, Rehman, Najeeb Ur, Al-Rawahi, Ahmed, Csuk, René, Khan, Husain Yar, Abbas, Ghulam, Al-Broumi, Mohammed Abdullah, Green, Ivan R, Elyassi, Ali, Mahmood, Talat, Al-Harrasi, Ahmed
• Format: Article
• Language: English
• Subjects: acetylcholinesterase; alpha-glucosidase; Antineoplastic Agents, Phytogenic - chemistry; Antineoplastic Agents, Phytogenic - isolation & purification; Antineoplastic Agents, Phytogenic - pharmacology; antioxidant activity; antioxidants; Apocynaceae; breast neoplasms; Cell Line, Tumor; cell proliferation; Cell Survival - drug effects; Cell Survival - physiology; Dose-Response Relationship, Drug; doxorubicin; enzyme inhibition; Female; glycosides; Glycosides - chemistry; Glycosides - isolation & purification; Glycosides - pharmacology; Humans; inhibition; inhibitory concentration 50; mass spectrometry; Medicine; neoplasm cells; nuclear magnetic resonance spectroscopy; Pharmacology/Toxicology; Pharmacy; Plant Extracts - chemistry; Plant Extracts - isolation & purification; Plant Extracts - pharmacology; Pregnanes - chemistry; Pregnanes - isolation & purification; Pregnanes - pharmacology; Research Article; sap; urease; 약학
• ISSN: 0253-6269; 1976-3786
• DOI: 10.1007/s12272-015-0653-0

The sap from the succulent Desmidorchis flava (N.E.Br) Meve and Liede yielded a new pregnane glycoside, named nizwaside whose structure was established using 1D and 2D NMR techniques as well as mass spectrometry (ESIMS). Nizwaside was tested for anticancer, DPPH antioxidant, urease enzyme inhibition, α-glucosidase enzyme inhibition and acetylcholinesterase inhibition activities. Interestingly, nizwaside showed significant anti-proliferative effects on MDA MB231 breast cancer cells with an IC₅₀ of 23.5 µg/ml. Moreover, nizwaside was more effective than Doxorubicin, a well-known clinical anticancer drug, in suppressing MDA MB231 cell proliferation even at concentrations lower than that of Doxorubicin (75 µg/ml nizwaside vs. 100 µg/ml Doxorubicin). On the other hand, nizwaside showed relatively weak antioxidant activity with 15 % inhibition.